Acadia
Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company developing and commercializing FDA-approved therapies for CNS and rare neurological disorders, including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome.
- Company typePublic
- Founded2009
- HeadquartersDallas, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Acadia does
Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company (NASDAQ: ACHC) headquartered in San Diego, California, that develops and commercializes prescription therapies for central nervous system (CNS) disorders and rare neurological diseases characterized by high unmet medical need. The company markets two FDA-approved products: NUPLAZID (pimavanserin), approved for Parkinson's Disease Psychosis (PDP), and DAYBUE (trofinetide), the first and only approved treatment for Rett syndrome. A new powder formulation, DAYBUE STIX, received FDA approval in December 2025 and entered broad availability in April 2026. Acadia's strategic focus is conditions where no approved therapies previously existed.
Acadia's portfolio is built on proprietary small-molecule pharmacology. Pimavanserin is a selective serotonin inverse agonist (SSIA) targeting the 5-HT2A receptor and was the first therapy approved specifically for PDP. Trofinetide is a synthetic analog of the C-terminal tripeptide of insulin-like growth factor 1 (IGF-1), with a powder formulation now extending the franchise. The clinical pipeline includes remlifanserin, a Phase 2 candidate for Alzheimer's Disease Psychosis, with topline data expected between August and October 2026. The pipeline also includes programs targeting CNS indications beyond the current two approved products, providing optionality on future revenue streams.
Acadia operates a sales-led specialty pharmaceutical model, reaching neurologists, psychiatrists, and movement disorder specialists through medical affairs outreach and distributing through specialty pharmacies and direct healthcare provider channels. FY2025 GAAP total revenues reached $1.07 billion (12% YoY growth), with FY2026 guidance of $1.22 to $1.28 billion. The company is profitable, reporting $274 million of Q4 2025 net income and $391 million of full-year 2025 net income. Distribution is currently concentrated in the United States, Canada, and Israel, with CHMP having recommended EU approval of DAYBUE in June 2026, signaling near-term geographic expansion into the United Kingdom, Germany, France, Italy, Spain, and Switzerland.
Acadia firmographics
Firmographics- Name
- Acadia
- Legal name
- Acadia Pharmaceuticals Inc.
- Website
- https://acadia.com
- Company type
- Public
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- Acadia Pharmaceuticals Inc. is a publicly traded biopharmaceutical company developing and commercializing FDA-approved therapies for CNS and rare neurological disorders, including NUPLAZID for Parkinson's Disease Psychosis and DAYBUE for Rett syndrome.
- Ownership category
- akta.pro rank
Acadia industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Neurology & Psychiatry (CNS) Pharmaceuticals (HLAIAAAF), Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD), Rare Pediatric & Congenital Disorder Therapies (HLAIAIAN)
Keywords
Where Acadia is headquartered
LocationHeadquarters
- HQ city
- Dallas
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Acadia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Operations, Marketing or Sales, Personnel, Supply Chain
Revenue model
- Pharmaceutical Product Sales: Acadia generates revenue primarily through the sale of prescription pharmaceutical products. The company reported full year 2025 GAAP total revenues of $1.07 billion, marking the first time the company surpassed $1 billion in annual revenue. Revenue is driven by NUPLAZID net sales ($760 to $790 million guidance for 2026) and DAYBUE net sales ($460 to $490 million guidance for 2026).
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Acadia product offering
Product offeringCore offering
Acadia Pharmaceuticals Inc. develops and commercializes FDA-approved prescription pharmaceutical treatments for central nervous system (CNS) disorders and rare neurological diseases. Its two marketed products are NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome, with the latter also available in a powder formulation (DAYBUE STIX). The company also maintains a clinical pipeline that includes a Phase 2 candidate (remlifanserin) for Alzheimer's Disease Psychosis.
Product overview
Acadia Pharmaceuticals Inc. is a pharmaceutical company focused on developing medicines for CNS disorders and rare diseases. The company markets two FDA-approved products: NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome (the first and only approved treatment for this rare neurodevelopmental disorder). DAYBUE is available in both oral solution and powder (STIX) formulations. The pipeline includes remlifanserin in Phase 2 for Alzheimer's disease psychosis, with results expected in late 2026. The company reported $1.07 billion in full-year 2025 GAAP total revenues, surpassing $1 billion for the first time, and issued 2026 guidance of $1.22 to $1.28 billion total revenues.
Differentiator
Problem solved
Functional benefit
Brands
- NUPLAZID: FDA-approved treatment for Parkinson's Disease Psychosis.
- DAYBUE
Products and services
- NUPLAZID (pimavanserin) FDA-approved prescription treatment for Parkinson's Disease Psychosis (PDP), a non-motor symptom impacting approximately half of people with Parkinson's over the course of their disease. Indicated for patients with Parkinson's Disease Psychosis.
- DAYBUE (trofinetide) FDA-approved prescription treatment for Rett syndrome, a rare genetic neurological and developmental disorder affecting movement, coordination, and communication. Available in oral solution formulation for adults and pediatric patients two years and older.
- DAYBUE STIX (trofinetide powder formulation) FDA-approved powder formulation of trofinetide for treating Rett syndrome in patients two years and older. Bioequivalent to the original DAYBUE oral solution with greater flexibility in administration. Over 80% satisfaction reported among early users during limited launch.
Quantifiable outcome
- First company to surpass $1 billion in annual revenue for Rett Syndrome and Parkinson's Disease Psychosis treatments.
- +3 more outcomes
Companies that use Acadia
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles2 records
Acadia technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Acadia partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered core and minor.
- CHMP (European Medicines Agency)coreThe Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency recommended approval for DAYBUE (trofinetide) in the European Union. Acadia is pursuing regulatory approval in Europe for the treatment of Rett syndrome.
- Jonathan M. PooleminorJonathan M. Poole was appointed to Acadia Pharmaceuticals' Board of Directors as a strategic governance update.
- Co-promotion PartnersminorAcadia collaborates with partners for co-promotion of products developed and marketed jointly. The company mentions partners for specific products or services including co-promotion arrangements.
Scale indicators8 records
Recent moves7 records
Expansion highlights6 records
Acadia competitors and assessment
Company assessmentDirect peers
- Intra-Cellular Therapies: Specialty CNS pharmaceutical company that developed and commercialized Caplyta (lumateperone) for schizophrenia and bipolar depression, mirroring Acadia's model of a focused CNS/psychiatry franchise with a single high-value specialty product promoted through specialty channels.
- Supernus Pharmaceuticals: Specialty CNS-focused pharma with a portfolio that includes products for Parkinson's disease (Apokyn), ADHD (Qelbree), and epilepsy — directly comparable to Acadia's CNS specialty commercial model and movement-disorder focus.
- Axsome Therapeutics: CNS specialty pharma commercializing Auvelity for major depressive disorder and other neurology assets — comparable in size, specialty distribution model, and CNS-focused GTM motion to Acadia.
- Sage Therapeutics: CNS-focused biopharma commercializing Zurzuvae for postpartum depression — similar specialty pharma profile with first-in-class CNS approvals, narrow product portfolios, and direct neurology/psychiatry HCP engagement.
- Jazz Pharmaceuticals: Specialty pharma with a CNS franchise (Xywav for narcolepsy) and rare disease focus (Epidiolex) — comparable to Acadia in commercial scale, specialty distribution, and dual CNS/rare disease focus.
- Neurocrine Biosciences: CNS specialty pharma commercializing Ingrezza (valbenazine) for tardive dyskinesia and other movement-disorder therapies — directly comparable movement-disorder and CNS focus with similar specialty-channel commercialization.
Broad incumbents
- Lundbeck: Global Danish-headquartered CNS specialty pharmaceutical company with a broader neurology/psychiatry portfolio than Acadia, but overlapping in CNS commercial channels and HCP targeting.
- UCB: Global biopharmaceutical company with a significant neurology and rare disease franchise (Vimpat, Keppra, Briviact, Rystiggo) — comparable CNS/neurology footprint but with broader therapeutic breadth and scale than Acadia.
- Teva Pharmaceutical Industries: Large generic/specialty pharma with a substantial CNS franchise (Austedo for Huntington's/tardive dyskinesia, Ajovy, Copaxone) — directly relevant to the movement-disorder neurology space while operating at much greater scale.
- Otsuka Pharmaceutical: Global pharma with a major CNS franchise including Abilify (aripiprazole) and the long-acting Abilify Asimtufii, plus CNS digital therapies — directly relevant to Acadia's psychiatry/neurology specialty positioning but at significantly greater size and breadth.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Acadia social profiles
Digital presenceAcadia compliance and trust
Trust signalCompliance3 records
Acadia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Acadia leadership team
Management profileNumber of profiles
Profiles4 records
Acadia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Acadia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Acadia
What does Acadia do?
Acadia Pharmaceuticals Inc. develops and commercializes FDA-approved prescription pharmaceutical treatments for central nervous system (CNS) disorders and rare neurological diseases. Its two marketed products are NUPLAZID (pimavanserin) for Parkinson's Disease Psychosis and DAYBUE (trofinetide) for Rett syndrome, with the latter also available in a powder formulation (DAYBUE STIX). The company also maintains a clinical pipeline that includes a Phase 2 candidate (remlifanserin) for Alzheimer's Disease Psychosis.
Is Acadia a public or private company?
Acadia is a public company. It is classified as public and is currently operating.
When was Acadia founded?
Acadia was founded in 2009. It employs 501 to 1,000 people.
Where is Acadia based?
Acadia is headquartered in Dallas, United States, in the North America region.
How does Acadia make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Acadia's main competitors?
Direct peers on record are Intra-Cellular Therapies, Supernus Pharmaceuticals, Axsome Therapeutics, Sage Therapeutics, Jazz Pharmaceuticals and Neurocrine Biosciences. Broad incumbents are Lundbeck, UCB, Teva Pharmaceutical Industries and Otsuka Pharmaceutical.
Does Acadia have an API?
No public API is recorded for Acadia.
What industry is Acadia in?
Acadia's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAAAF, Neurology & Psychiatry (CNS) Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.